TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2371814

Group type: EXPERIMENTAL
Intervention: Goretex reconstruction
Number of subjects: 41

Group type: COMPARATOR
Intervention: Kennedy Ligament Augmentation Device (LAD)
Number of subjects: 41
Study: 7015842

Group type: EXPERIMENTAL
Intervention: coherin
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31612193

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 80
Study: 28434871

Group type: EXPERIMENTAL
Intervention: Volitional helpsheet (VHS) plus usual treatment
Number of subjects: 518

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 518
Study: 27198953

Group type: EXPERIMENTAL
Intervention: Suvorexant (20/15 mg and 40/30 mg)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1482
Study: 24442244

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus autologous stem cell transplant (ASCT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rituximab, fludarabine, and cyclophosphamide (R-FC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus ASCT
Number of subjects: 96

Group type: COMPARATOR
Intervention: R-FC
Number of subjects: 96
Study: 21705921

Group type: EXPERIMENTAL
Intervention: Functional stabilization training (8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 28
Study: 19335882

Group type: EXPERIMENTAL
Intervention: Topical wound treatment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Exponential model of wound healing
Number of subjects: 338
Study: 17334274

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study: 14722673

Group type: EXPERIMENTAL
Intervention: id (99m)Tc-HIG
Number of subjects: 12

Group type: COMPARATOR
Intervention: sc (99m)Tc-HIG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: id (99m)Tc-nanocolloid
Number of subjects: 12

Group type: COMPARATOR
Intervention: sc (99m)Tc-nanocolloid
Number of subjects: 12
Study: 11408386

Group type: EXPERIMENTAL
Intervention: Nifedipine once daily
Number of subjects: 201

Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg, amiloride 2.5 mg)
Number of subjects: 201
Study: 9431484

Group type: EXPERIMENTAL
Intervention: Electrostimulation of the vagus afferent endings (ENS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no ENS)
Number of subjects: 10
Study: 8231842

Group type: EXPERIMENTAL
Intervention: LDL3 cholesterol level
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HDL3 cholesterol level
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LDL3 cholesterol level < 1.8 mmol/L
Number of subjects: 74
Study: 3305591

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 29737068

Group type: EXPERIMENTAL
Intervention: Low concentration contrast agent combined double low dose (80 kV, 15 mL, 320 mg I/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (120 kV, 50 mL, 370 mg I/mL)
Number of subjects: 60
Study: 27352490

Group type: EXPERIMENTAL
Intervention: Gold hook fishing acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study: 24996524

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SMO) for 10 days
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oxazepam for 10 days
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SMO)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 126
Study: 21861080

Group type: EXPERIMENTAL
Intervention: Endovascular coiling for ruptured cerebral aneurysms
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Dome size ≥7.5 mm
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pre-treatment aneurysm re-rupture
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Non-small size/small neck aneurysm (dome size ≥10 mm or neck size ≥4 mm)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Residual aneurysms on immediate post-coiling angiograms
Number of subjects: 129
Study: 20214061

Group type: EXPERIMENTAL
Intervention: Balanced muscular tension needling method
Number of subjects: 106

Group type: COMPARATOR
Intervention: Routine acupuncture method
Number of subjects: 106
Study: 16965889

Group type: EXPERIMENTAL
Intervention: GOES treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 16238662

Group type: EXPERIMENTAL
Intervention: Intervention for child only
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intervention for child and parent
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study: 11855379

Group type: EXPERIMENTAL
Intervention: Back pain patients during left axial rotation exertion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Back pain patients during right axial rotation exertion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched controls during axial rotation exertion
Number of subjects: 24
Study: 10885864

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg per day
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 8625152

Group type: EXPERIMENTAL
Intervention: Combined cisplatin-based chemotherapy and radiotherapy
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Combined noncisplatin-based chemotherapy and radiotherapy
Number of subjects: 1887

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1887
Study: 1689558

Group type: EXPERIMENTAL
Intervention: 6% HES 450,000/0.7
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% HES 200,000/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3% HES 200,000/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% HES 40,000/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% HES 200,000/0.5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% HES 200,000/0.62
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 6928739

Group type: EXPERIMENTAL
Intervention: Orthodontic force application
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no orthodontic force)
Number of subjects: 17
Study: 31377702

Group type: EXPERIMENTAL
Intervention: Sensorimotor training for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive control training for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive control training
Number of subjects: 60
Study: 27747986

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.64% ARA and various concentrations of DHA: 0.32%, 0.64%, or 0.96%)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no LCPUFA)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 69
Study: 26371404

Group type: EXPERIMENTAL
Intervention: 8-week exercise intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 135
Study: 23758126

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-monitored plasma glucose (control)
Number of subjects: 60
Study: 21718999

Group type: EXPERIMENTAL
Intervention: Sepraspray Adhesion Barrier (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 41
Study: 19121772

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH diet with 50 mmol/day sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium reduction‐plus‐weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced dietary sodium intake
Number of subjects: 0
Study: 17523995

Group type: EXPERIMENTAL
Intervention: Individually tailored smoking cessation advice letters
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Usual care (telephone counselling and an information pack)
Number of subjects: 1508
Study: 14668568

Group type: EXPERIMENTAL
Intervention: Twice-daily lisinopril (5-20 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Once-daily lisinopril (5-20 mg/d)
Number of subjects: 32
Study: 11181127

Group type: EXPERIMENTAL
Intervention: 6-month short-course therapy for tuberculosis including rifampin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 6-month short-course therapy for tuberculosis without HIV infection
Number of subjects: 6
Study: 9833167

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (antihypertensive drug)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Restrictive antihypertensive therapy (control)
Number of subjects: 500
Study: 8058004

Group type: EXPERIMENTAL
Intervention: Escherichia coli L‐asparaginase
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erwinia chrysanthemi L‐asparaginase
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both E. coli and Erwinia L‐asparaginase
Number of subjects: 20
Study: 4004503

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Drug counseling
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Therapist personal qualities
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Helping Alliance Questionnaire (early-in-treatment measure)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Purity of therapy techniques
Number of subjects: 9
Study: 31403327

Group type: EXPERIMENTAL
Intervention: Measuring anticipated regret (AR) prior to intention
Number of subjects: 803

Group type: COMPARATOR
Intervention: Measuring anticipated regret (AR) after intention
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Trait reactance
Number of subjects: 803
Study: 30010931

Group type: EXPERIMENTAL
Intervention: Empirical antifungal therapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pre-emptive antifungal therapy
Number of subjects: 149
Study: 25410474

Group type: EXPERIMENTAL
Intervention: Carnoy's solution (CS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10% neutral buffered formalin (NBF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Residual fat group (from NBF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: NBF and Retrospective groups
Number of subjects: 50
Study: 23787221

Group type: EXPERIMENTAL
Intervention: Underbody warming system
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no warming)
Number of subjects: 110
Study: 22545821

Group type: EXPERIMENTAL
Intervention: Narrative Enhancement/Cognitive Therapy (NECT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: NECT (exposed participants)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: NECT (unexposed participants)
Number of subjects: 39
Study: 19930236

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Information-advice (Control)
Number of subjects: 184
Study: 17490978

Group type: EXPERIMENTAL
Intervention: Fish-oil (FO) supplementation (0.5 g DHA and 0.15 g EPA)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: MTHF supplementation (400 microg methyltetrahydrofolic acid)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 311
Study: 18160753

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 84
Study: 15485474

Group type: EXPERIMENTAL
Intervention: PC-coated stents
Number of subjects: 502

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 502

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 502
Study: 10829315

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy in combination with RO-resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 0
Study: 8785149

Group type: EXPERIMENTAL
Intervention: ondansetron 0.06 mg kg‐1 i.v.
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.2 mg kg‐1 i.m.
Number of subjects: 282

Group type: COMPARATOR
Intervention: prochlorperazine 0.1 mg kg‐1 i.v.
Number of subjects: 282
Study: 1356864

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 63
Study: 3886141

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (50 mg during the first week, and 100 mg thereafter, at bedtime)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cimetidine (1,200 mg/day in four divided doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride and Cimetidine
Number of subjects: 21
Study: 30318393

Group type: EXPERIMENTAL
Intervention: saline + NE (5 μg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: phentolamine + NE (2.5 mg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline + saline
Number of subjects: 24
Study: 28280053

Group type: EXPERIMENTAL
Intervention: Copeptin levels measured in patients with eGFR 60-89 mL/min/1.73 m2
Number of subjects: 4372

Group type: EXPERIMENTAL
Intervention: Copeptin levels measured in patients with more advanced renal disease
Number of subjects: 4372

Group type: COMPARATOR
Intervention: Copeptin levels measured in patients with normal renal function
Number of subjects: 4372
Study: 27129606

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intranasal midazolam
Number of subjects: 40
Study: 24853591

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) - Hyalgan intra-articular injection, Sodium hyaluronate 10 mg/ml, 2 ml injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tenoxicam (TX) - Tilcotil flacon, 20 mg tenoxicam/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Betamethasone (CS) - Diprospan flacon, 7.0 mg betamethasone/1 ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group - Saline solution injected intra-articularly
Number of subjects: 100
Study: 22889234

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 99

Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cerclage (in women with CL < 15 mm)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No cerclage (in women with CL < 15 mm)
Number of subjects: 99
Study: 19127069

Group type: EXPERIMENTAL
Intervention: High-sulphite wine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-sulphite wine
Number of subjects: 8
Study: 17389492

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured at 5200 m after acute exposure
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured at baseline and postexpedition at sea-level
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) measured at 5200 m
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) at altitude
Number of subjects: 76
Study: 15562061

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 33

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 33
Study: 11495396

Group type: EXPERIMENTAL
Intervention: rTMS at 20 Hz for 2 seconds over 20 trains at 80% of motor threshold
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment (placebo stimulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (active and sham treatment)
Number of subjects: 20
Study: 9422453

Group type: EXPERIMENTAL
Intervention: Single Axis prosthetic foot
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Seattle Lite prosthetic foot
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flex Foot prosthetic foot
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (individuals without transtibial amputations)
Number of subjects: 10
Study: 7894539

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparative drugs (benzodiazepines)
Number of subjects: 0
Study: 3310750

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline (6 micrograms/kg, two times at an hour interval)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (0.1 mg/kg, two times)
Number of subjects: 23
Study: 29807126

Group type: EXPERIMENTAL
Intervention: Exercise (cycling for 1 hour at 50% of maximum oxygen uptake)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (3 hours of rest)
Number of subjects: 16
Study: 27272608

Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combined intervention (parent + teacher)
Number of subjects: 199
Study: 24576432

Group type: EXPERIMENTAL
Intervention: Inferior vena cava filter insertion
Number of subjects: 371

Group type: COMPARATOR
Intervention: No inferior vena cava filter insertion (control)
Number of subjects: 371
Study: 22357133

Group type: COMPARATOR
Intervention: Maximal strength training
Number of subjects: 10
Study: 20097039

Group type: EXPERIMENTAL
Intervention: Bipolar Sealer 6.0‐VT (BPS 6.0‐VT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional electrocautery (Erbe ICC 350)
Number of subjects: 105
Study: 18036807

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1800 mg daily for 4 months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 16899602

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Epirubicin + Tamoxifen
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CAIX positivity in HIF-1alpha-negative tumors
Number of subjects: 187
Study: 12134127

Group type: EXPERIMENTAL
Intervention: 3% fenticonazole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% fenticonazole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100000UI nystatin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole
Number of subjects: 80
Study: 10453632

Group type: EXPERIMENTAL
Intervention: Wet scraping and HEPA vacuuming
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dry scraping followed by dry sweeping
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Wet scraping and HEPA vacuuming with portable HEPA-filtered exhaust fan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 6
Study: 8845325

Group type: EXPERIMENTAL
Intervention: Loading dose of medroxyprogesterone acetate (1000 mg p.o. q.d.s. for 48 h)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Oral maintenance dose of 1000 mg daily
Number of subjects: 211

Group type: COMPARATOR
Intervention: Oral maintenance dose of 500 mg daily
Number of subjects: 211
Study: 2212796

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 495086

Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg t.i.d. for three days) in Study I (50 patients)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg t.i.d. for two months) in Study II (31 patients)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Flunarizine (weekly decreasing doses for three months) in Study III (9 patients with vertigo of recent origin)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (weekly decreasing doses for three months) in Study III (18 patients with vertigo of recent origin)
Number of subjects: 99
Study: 30427232

Group type: EXPERIMENTAL
Intervention: 2 mM quinine (Bitter1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mM quinine (Bitter2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sweet solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bitter1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bitter2
Number of subjects: 9
Study: 28802290

Group type: EXPERIMENTAL
Intervention: Encover® 400 ml/day for 8 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 174
Study: 26510186

Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) solution
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional solutions
Number of subjects: 64
Study: 23968123

Group type: EXPERIMENTAL
Intervention: Dopamine partial Agonist, Aripiprazole
Number of subjects: 0
Study: 20570490

Group type: EXPERIMENTAL
Intervention: 5 sessions of attention shaping
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1, 3, or 5 sessions of attention shaping
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Attention shaping program performance
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Eye tracking pre and post-tests
Number of subjects: 29
Study: 19874593

Group type: EXPERIMENTAL
Intervention: H-Wave device stimulation (HWDS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 22
Study: 17171416

Group type: EXPERIMENTAL
Intervention: Tubeless PNL
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard PNL
Number of subjects: 35
Study: 15522378

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide sub‐Tenon's capsule injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% prednisolone eyedrops
Number of subjects: 100
Study: 11504661

Group type: EXPERIMENTAL
Intervention: Intermittent parathyroid hormone (PTH) administration
Number of subjects: 0
Study: 9438594

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly 5-fluorouracil chemotherapy
Number of subjects: 0
Study: 8403669

Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated methylmethacrylate beads
Number of subjects: 28

Group type: COMPARATOR
Intervention: Systemic antibiotics alone
Number of subjects: 28
Study: 2936282

Group type: EXPERIMENTAL
Intervention: Ipratropium aerosol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24